Tezepelumab for the treatment of chronic spontaneous urticaria: Results of the phase 2b INCEPTION study

Although the 16-week primary end point was not met, tezepelumab showed post-treatment reductions in CSU activity through week 32, suggesting a delayed, sustained, thymic stromal lymphopoietin blockade treatment effect.